Discrepancy Between Cardiac and Physical Functional Reserves in Stroke

Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Stroke (Impact Factor: 5.72). 02/2012; 43(5):1422-5. DOI: 10.1161/STROKEAHA.111.649434
Source: PubMed


Understanding the physiological limitations to exercise after stroke will assist the development of targeted therapies to improve everyday function. This study defines (1) whether exercise capacity is limited by the cardiovascular system (oxygen supply) or skeletal muscles (oxygen utilization); and (2) cardiac function and pumping capability in people with stroke.
Twenty-eight male participants with mild ischemic stroke (70 ± 6 years of age, 18 ± 20 months poststroke) and 25 male, age-matched healthy control subjects performed a graded cardiopulmonary exercise test with gas exchange and noninvasive hemodynamic measurements. Maximal oxygen extraction was calculated as the ratio between peak oxygen consumption and peak cardiac output. Cardiac function and pumping capability were assessed by peak exercise cardiac power output (expressed in watts) and cardiac output.
Peak oxygen consumption (18.4 ± 4.6 versus 26.8 ± 5.5 mL/kg/min, P<0.01) and arterial-venous O(2) difference (9.3 ± 2.5 versus 12.6 ± 1.9 mlO(2)/100 mL of blood, P<0.01) were both reduced in stroke participants compared with healthy control subjects. In contrast, peak exercise cardiac power output (4.79 ± 0.79 versus 4.51 ± 0.96 W, P=0.49), cardiac output (16.4 ± 3.1 versus 17.1±2.5 L/min, P=0.41), and the pressure-generating capacity of the heart (127±11 versus 125 ± 14 mm Hg, P=0.97) were similar between stroke participants and healthy control subjects.
The ability of skeletal muscles to extract oxygen is diminished after stroke. However, cardiac function and pumping capability are maintained. Appropriate therapies targeting muscle oxygen uptake such as exercise rehabilitation may improve exercise capacity after stroke.

Download full-text


Available from: Sarah Moore, Aug 07, 2014
  • Source
    • "Mitochondrial mutation load was assessed using urinary epithelial cells [12]. Physiological markers of mitochondrial disease were collected as part of a larger exercise study (manuscript in preparation) as follows: (1) energy expenditure was assessed using a body-worn multi-sensor array (SenseWear Pro3, Bodymedia Inc, Pennsylvania, USA 2.5), which was worn by the participant for seven days in the community; (2) exercise capacity (peak oxygen consumption) was evaluated using cardiopulmonary exercise testing, which was performed as previously reported [13] (During all visits, a stepped incremental workload test (~10–20 W/min) was conducted to elicit a symptom-limited maximum oxygen uptake and heart rate response); (3) muscle strength testing evaluated hip flexor and extensor strength and was performed by the same investigator (JN) using an isokinetic dynamometer (CSMI HUMAC®/NORM testing and rehabilitation system) at a speed of 60°/s [ 14]. (Participants underwent familiarization with six sub-maximal contractions and then performed six maximal repetitions with consistent verbal encouragement); and (4) where available, brain MRI images were reviewed (GSG) for the presence or absence of global cerebellar atrophy retrospectively. GSG was blinded to the gait results but not genotype at the time of assessment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondrial disease is complex and variable, making diagnosis and management challenging. The situation is complicated by lack of sensitive outcomes of disease severity, progression, contributing pathology and clinical efficacy. Gait is emerging as a sensitive marker of pathology; however, to date, no studies have quantified gait in mitochondrial disease. In this cross-sectional study, we quantified gait characteristics in 24 patients with genetically confirmed mitochondrial disease (m.3243A>G and m.8344A>G) and 24 controls. Gait was measured using an instrumented walkway according to a predefined model with five domains hypothesised to reflect independent features of the neural control of gait in mitochondrial disease, including: pace (step velocity and step length); rhythm (step time); variability (step length and step time variability); asymmetry (step time asymmetry); and postural stability (step width, step width variability and step length asymmetry). Gait characteristics were compared with respect to controls and genotype. Additional measures of disease severity, pathophysiology and imaging were also compared to gait to verify the validity of gait characteristics. Discrete gait characteristics differed between controls and mitochondrial disease groups, even in relatively mildly affected patients harbouring the m.3243A>G mutation. The pattern of gait impairment (increased variability and reduced postural control) was supported by significant associations with measures of disease severity, progression, pathophysiology and radiological evidence of cerebellar atrophy. Discrete gait characteristics may help describe functional deficits in mitochondrial disease, enhance measures of disease severity and pathology, and could be used to document treatment effects of novel therapies.
    Full-text · Article · Oct 2013 · Journal of Neurology
  • Source

    Preview · Article · Jun 2012 · Stroke
  • Source

    Full-text · Article · Aug 2012 · Stroke
Show more